Home › RICHARD-ALLAN SCIENTIFIC COMPANY › Epredia

Epredia

RICHARD-ALLAN SCIENTIFIC COMPANY · Model Reticulocyte Stain · UDI-DI 00673693090469

510(k) clearances

Adverse events

Recalls

Facilities

Description

In 1949, Dr. George Brecher developed a stain called new methylene blue to identify immature erythrocytes (reticulocytes) based upon aggregations of RNA within disintegrating ribosomes. This RNA is at its highest level immediately after enucleation of the cell and continues to decrease until its complete absence in the fully mature erythrocyte. Reticulocytes are so named due to their mesh-like (reticular) network of ribosomal RNA which, after staining, is readily visible with a blue granulofilamentous appearance. The quantitative evaluation of reticulocytes in peripheral blood is an important test used in the assessment of erythropoiesis, bone marrow function, and anemia typing.

Recalls

Date	Firm	Reason
2004-06-24	ABX Diagnostics Inc	Power failure having impact on software.

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API key Read the docs

Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.